Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Atherosclerosis

Volumn 204, Issue 2, 2009, Pages 515-520

  Amarenco, Pierre ^a   Goldstein, Larry B ^b   Callahan III, Alfred ^c   Sillesen, Henrik ^d   Hennerici, Michael G ^e   O'Neill, Blair J ^f   Rudolph, Amy E ^g   Simunovic, Lisa ^g   Zivin, Justin A ^h   Welch, K M A ⁱ  

^a INSERM   (France)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Neurologic Consultants   (United States)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f DALHOUSIE UNIVERSITY   (Canada)

^g PFIZER INC   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

HDL C; LDL C; Statin; Stroke; TIA

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FEMALE; FOLLOW UP; HEMORRHAGIC STROKE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RECURRENT DISEASE; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PYRROLES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; STROKE; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 67349087272     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.09.008     Document Type: Article

References (22)

1. Lewington S., Clarke R., Qizilbash N., et al., Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
2. Gueyffier F., Bulpitt C., Boissel J.P., et al., for the INDANA Group. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet 353 (1999) 793-796
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041
4. Lewington S., Whitlock G., Clarke R., et al., Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370 (2007) 1829-1839
5. Amarenco P., Lavallée P., and Touboul P.-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 3 (2004) 271-278
6. Amarenco P., Labreuche J., Lavallée P., and Touboul P.-J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35 (2004) 2902-2909
7. Baigent C., Keech A., Kearney P.M., et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
8. Amarenco P., Bogousslavsky J., Callahan III A., et al., Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 (2006) 549-559
9. Amarenco P., Goldstein L.B., Szarek M., et al., SPARCL Investigators. Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 38 (2007) 3198-3204
10. Amarenco P., Labreuche J., and Touboul P.-J. High-density lipoprotein cholesterol and risk of stroke and carotid atherosclerosis: a systematic review. Atherosclerosis 196 (2008) 489-496
11. Amarenco P., Bogousslavsky J., Callahan A.S., et al., SPARCL Investigators. Design and baseline characteristics of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) study. Cerebrovasc Dis 16 (2003) 389-395
12. Patel A., Woodward M., Campbell D.J., et al. Plasma lipids predict myocardial infarction, but not stroke, in patients with established cerebrovascular disease. Eur Heart J 26 (2005) 1910-1915
13. Amarenco P. Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction. Neurology 57 5 Suppl. 2 (2001) S35-S44
14. Iso H., Jacobs Jr. D.R., Wentworth D., et al., for the MRFIT Research Group. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320 (1989) 904-910
15. Lindenstrøm, Boysen G., and Nyboe J. Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ 309 (1994) 11-15
16. Tirschwell D.L., Smith N.L., Heckbert S.R., et al. Association of cholesterol with stroke risk varies in stroke subtypes and patient subgroups. Neurology 63 (2004) 1868-1875
17. Amarenco P., Labreuche J., Elbaz A., et al., GENIC Investigators. Blood lipids in brain infarction subtypes. Cerebrovasc Dis 22 (2006) 101-108
18. Hankey G.J., Jamrozik K., Broadhurst R.J., et al. Five-year survival after first-ever stroke and related prognostic factors in the Perth Community Stroke Study. Stroke 31 (2000) 2080-2086
19. Amarenco P., and Steg P.G. The paradox of cholesterol and stroke. Lancet 370 (2007) 1803-1804
20. Yusuf S., Hawken S., Ôunpuu S., et al., INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet 364 (2004) 937-952
21. Walldius G., Aastveit A.H., and Jungner I. Stroke mortality and the apoB/apoA-I ratio: results of the AMORIS prospective study. J Intern Med 259 (2006) 259-266
22. Collins R., Armitage J., Parish S., et al., Heart Protection Study Collaborative Group. Effect of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 363 (2004) 757-767